X4 Pharmaceuticals (XFOR) initiates a Phase 1b clinical trial evaluating lead candidate mavorixafor (X4P-001), combined with AbbVie’s (ABBV -0.4%) Imbruvica (ibrutinib), for the treatment of a rare form of non-Hodgkin lymphoma (NHL) called Waldenström’s macroglobulinemia (WM).
The objectives of the ~15-subject open-label, dose-escalation study are changes in serum immunoglobulin M (IgM) and hemoglobin levels from baseline, both biomarkers of clinical response.
Mavorixafor is a small molecule antagonist of a protein called chemokine receptor type 4 (CXCR4) which is present in 30-40% of WM patients.
Related ticker: Johnson & Johnson (JNJ -0.2%)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.